PPMS and SPMS: Epidemiology and Market Forecasts to 2030 by Pharmascroll

"PPMS and SPMS: Epidemiology and Market Forecasts to 2030" reports cover in depth disease
insights, epidemiology overview and markets and drug forecasts country wise till 2030.

Hyderabad, India, April 25, 2018 --(PR.com)-- Multiple Sclerosis is an autoimmune disorder that
happens in the Central nervous system of the body. Multiple Sclerosis involves the brain, optic nerves and
the spinal cord and leads to the destruction of the insulation layer, Myelin, which covers the nerve fibers
in the CNS.

SPMS: Epidemiology and Market Forecasts to 2030

SPMS is characterized by a continuous increase in disability and worsening of symptoms with or without
the period of relapses and remissions. As per the latest report by Pharmascroll, SPMS- A Detailed
Overview, nearly 50% of RRMS patients progress to SPMS in a 10 year time period. In SPMS, the
patients might not have relapses at all but the symptoms may not completely go off (plateau) in the
remission period.

The report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of
Secondary Progressive MS in the US, EU5, and Japan and the historical & forecasted market size of
SPMS drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France,
Italy, Spain, UK), Australia and Canada till 2030.

Drugs covered:
Laquinimod
Lemtrada
Masitinib
Ocrelizumab
Tysabri
Siponimod
Zinbryta
Mitoxantrone

SPMS Epidemiology:
As per the report, SPMS is prevalent in around 30% of the MS patients and around 50% of RRMS
patients move on to progress to the SPMS stage in a span of around 10 years and around 85% of the
patients progress to SPMS stage in the span of 15-20 years. The report provides the overview of SPMS
diagnosed prevalent and treated patients in the US, EU5 and Japan markets year wise starting from 2015
till 2024.

Market Forecast in $ Sales and Patient numbers:

The report forecasts that the SPMS market is projected to reach over $3 Bn by 2022 primarily due to the
uptake of key molecules including Siponimod and Ocrevus in SPMS.The report provides sales and
patient numbers forecast for the overall SPMS market and drug wise forecasts from 2015 till 2030 at

Page 1/4
PR.com Press Release Distribution Terms of Use
Global level and in the US, EU5, Australia and Canada markets.

The report can be checked at ÿhttps://pharmascroll.com/product/spms-detailed-overview/

PPMS: Epidemiology and Market Forecasts to 2030

Primary progressive multiple sclerosis is primarily characterized by progression of disease activity and
the disability amongst the patients. As per the latest report by Pharmascroll, PPMS- A Detailed Overview,
nearly 10-15% of the multiple sclerosis patients are Primary Progressive MS patients. The Primary
Progressive MS patients might have an active or non-active progression of disease.

This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of
Primary Progressive MS in the US, EU5, and Japan and the historical & forecasted market size of PPMS
drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy,
Spain, UK), Australia and Canada till 2030.

Drugs covered:
Laquinimod
Ocrelizumab
Masitinib
Lemtrada
Qizenday
Ibudilast
Idebenone

PPMS Epidemiology:
As per the report, nearly 10-15% of the Multiple Sclerosis patients are PPMS patients and in the US,
around 12-13% of the MS patients are PPMS patients. The report provides the overview of PPMS
diagnosed prevalent and treated patients in the US, EU5 and Japan market year wise starting from 2015
till 2024.

Market Forecast in $ Sales and Patient numbers:

The report forecasts that the PPMS market is projected to reach over $2 Bn by 2024 primarily due to the
launch and uptake of key molecules including Ocrevus in PPMS. The report provides sales and patient
numbers forecast for the overall PPMS market and drug wise forecasts from 2015 till 2030 at Global level
and in the US, EU5, Australia and Canada markets.

The report can be checked at https://pharmascroll.com/product/ppms-detailed-overview/

Why Purchase the Reports:

· Robust Market and Drug forecast available at country level
· Forecast in terms of both $ sales and Patient Numbers
· Current and Forecasted Drug treated and Diagnosed Prevalent Patient pool
· Detailed Drug Attribute analysis on multiple Clinical Parameters

Page 2/4
PR.com Press Release Distribution Terms of Use
· Multiple Countries coverage
· Current Marketed and Pipeline Drugs coverage
· Detailed Disease Insights coverage

To purchase the reports at a special bundle pack price offer, the interested buyers can write back to the
company at enquiry@pharmascroll.com

About Pharmascroll:
Pharmascroll is a diligent business consulting and market research firm focused solely towards
pharmaceutical markets. The company consults and researches in majorly chronic disease indications
prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide
analytical and logical answers to the key business questions of the pharmaceutical and medical insights
teams and to make better informed business decisions with the detailed relevant information available.

Page 3/4
PR.com Press Release Distribution Terms of Use
Contact Information:
Pharmascroll Research and Consulting Private Limited
Bhawna Gupta
+919776868067
Contact via Email
www.pharmascroll.com

Online Version of Press Release:

You can read the online version of this press release at: https://www.pr.com/press-release/751505

Page 4/4
PR.com Press Release Distribution Terms of Use